IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Pancreatic Neuroendocrine Neoplasm
Fudan Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Pancreatic Neuroendocrine Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lanreotide Federation Francophone de Cancerologie Digestive | Phase 2/3 | B |
Sargramostim Roswell Park Cancer Institute | Phase 2 | CCC |
Survaxm Roswell Park Cancer Institute | Phase 2 | CCC |
Ifa Roswell Park Cancer Institute | Phase 2 | CCC |
Everolimus Novartis Pharmaceuticals | Phase 1 | CC |
View all 10 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →